<!DOCTYPE html><html><head><title>Epilepsy: percentage of females over 12 years given antiepileptic drugs, who had documented evidence of discussion of pregnancy or contraception.</title><link rel="stylesheet" type="text/css" href="style.css"></head><body><div class='section'>
<h2>General
</h2>
<div class='field field_text'>
<h3>
Title
</h3>
<div class='FieldValue'>
<div class="content_title">Epilepsy: percentage of females over 12 years given antiepileptic drugs, who had documented evidence of discussion of pregnancy or contraception.</div>
</div>

</div>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>The Royal College of Paediatrics and Child Health. Epilepsy12 national report, round 2. London (UK): The Royal College of Paediatrics and Child Health; 2014 Nov. 103 p. </td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>The Royal College of Paediatrics and Child Health. Epilepsy12, round 2. Full methodology document. London (UK): The Royal College of Paediatrics and Child Health; 2013 Jun. 33 p. </td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Measure Domain
</h2>
<div class='field field_picklist-one'>
<h3>
Primary Measure Domain
</h3>
<div class='FieldValue'>
Clinical Quality Measures: Process
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Secondary Measure Domain
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>

</div>
<div class='section'>
<h2>Brief Abstract
</h2>
<div class='field field_text'>
<h3>
Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measure is used to assess the percentage of females over 12 years given antiepileptic drugs (AEDs), who had documented evidence of discussion of pregnancy or contraception.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Rationale
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Epilepsies are amongst the most common significant long-term health conditions of childhood and pose significant challenges for the National Health Service. The Epilepsy12 audit has demonstrated significant improvement in care during its first five years. </p>
<p>Age of greater than 12 is a pragmatic way of defining adolescence or 'childbearing' age.</p>
<p><strong>Recommendations</strong></p>
<p>In girls of childbearing potential, including young girls who are likely to need treatment into their childbearing years, the risk of the drugs causing harm to an unborn child should be discussed with the child and/or her carer, and an assessment made as to the risks and benefits of treatment with individual drugs (National Institute for Health Clinical Excellence [NICE], 2012).</p>
<p>Adolescent girls taking antiepileptic drugs (AEDs) and their parents should be advised of the risks of fetal malformations and developmental delay (Scottish Intercollegiate Guidelines Network [SIGN], 2005). </p></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Rationale
</h3>
<div class='FieldValue'>
<table><tr><td>National Institute for Health and Clinical Excellence (NICE). The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. London (UK): National Institute for Health and Clinical Excellence (NICE); 2012 Jan. 117 p.&nbsp;(Clinical guideline; no. 137).&nbsp;</td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of epilepsies in children and young people. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN); 2005 Mar. 53 p.&nbsp;(SIGN publication; no. 81).&nbsp; [279 references]</td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>The Royal College of Paediatrics and Child Health. Epilepsy12 national report, round 2. London (UK): The Royal College of Paediatrics and Child Health; 2014 Nov. 103 p. </td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Primary Health Components
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Epilepsy; pregnancy; contraception; antiepileptic drugs (AEDs); children</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Female children 12 years and more who were commenced on antiepileptic drugs (AEDs) (see the related "Denominator Inclusions/Exclusions" field)</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Female children 12 years and more who were commenced on antiepileptic drugs (AEDs) who had evidence of discussion regarding pregnancy and/or contraception</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Evidence Supporting the Measure
</h2>
<div class='field field_picklist-choice'>
<h3>
Type of Evidence Supporting the Criterion of Quality for the Measure
</h3>
<div class='FieldValue'>
A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence
</div>
<div class='FieldValue'>
One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal
</div>

</div>
<div class='field field_text'>
<h3>
Additional Information Supporting Need for the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Extent of Measure Testing
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Epilepsy12 Round 2 is the second cycle of this audit which aimed to re-examine the quality of care for children and young people with epilepsies in the United Kingdom (UK).</p>
<p><strong>Clinical Audit Key Findings</strong></p>
<p>In the Clinical Audit Domain 12 clinical performance indicators were applied to a cohort of 3,449 children for whom a 'first paediatric assessment' for a 'paroxysmal episode or episodes' was undertaken during the four months between 1 January and 30 April 2013. In Round 1 the cohort was identified similarly but across a six-month period from 1 August 2009 to 31 January 2010.</p>
<p><strong>Clinical Audit Performance Indicator Key Findings</strong></p>
<p>Ten of the 12 performance indicators were defined identically to those used in Round 1 and were applied to a similarly defined cohort of children in Round 2. Of the 10 clinical performance indicators where longitudinal comparison was possible across rounds, 9 indicators showed a statistically significant improvement across the UK (tertiary involvement being the exception&ndash;point 3 on the chart). The 12 performance indicators results for both rounds are summarised in the original measure documentation.</p>
<p><strong>Recruitment</strong></p>
<p>The audit covered England, Northern Ireland, Scotland and Wales. All paediatric services that employ NHS paediatricians that request electroencephalograms (EEGs) and are involved with the care of children and young people with seizures or epilepsy were invited to participate. During Round 1, the UK was split into pragmatic regions and 'audit units'. Each 'audit unit' had defined: Consultant Paediatricians (one of whom acting as the audit unit lead); National Health Service (NHS) Health Boards, Trusts; Hospitals; Community Paediatric services and EEG services. Audit units invited to participate in Round 1 were also invited to participate in Round 2.</p>
<p><strong>Data and Quality Analysis</strong></p>
<p>The data collection system included validation rules to ensure that appropriate and internally consistent data was provided by the participating units. This meant that the overall data quality standard was high. Six records were removed from the dataset as the first paediatric assessment had taken place when the child was less than one month old or an implausible age at first paediatric assessment was recorded. Audit units were able to view provisional data and provide corrected data where appropriate. </p>
<p>The Epilepsy12 indicators are reported with 95% confidence intervals. The Wilson score method has been used to calculate confidence intervals. The confidence intervals can be used to assess whether there has been a statistically significant change in between Round 1 and Round 2 or between countries. If the 95% confidence intervals do not overlap the difference is statistically significant. Individual Audit Units are identified as a positive outlier (statistically significantly higher than the UK value) if the unit's upper 95% confidence interval is below the lower confidence interval for the UK. This is equivalent to being approximately two standard deviations above the UK value. Units are identified as a negative outlier (statistically significantly lower than the UK value) if the unit's lower 95% confidence interval is above the upper confidence interval for the UK. This is equivalent to being approximately two standard deviations below the UK value.</p>
<p>Refer to the original measure documentation for performance indicator results and key findings.</p></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Extent of Measure Testing
</h3>
<div class='FieldValue'>
<table><tr><td>The Royal College of Paediatrics and Child Health. Epilepsy12 national report, round 2. London (UK): The Royal College of Paediatrics and Child Health; 2014 Nov. 103 p. </td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>State of Use of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
State of Use
</h3>
<div class='FieldValue'>
Current routine use
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Current Use
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>

</div>
<div class='section'>
<h2>Application of the Measure in its Current Use
</h2>
<div class='field field_picklist-choice'>
<h3>
Measurement Setting
</h3>
<div class='FieldValue'>
Ambulatory/Office-based Care
</div>
<div class='FieldValue'>
Ambulatory Procedure/Imaging Center
</div>
<div class='FieldValue'>
Emergency Department
</div>
<div class='FieldValue'>
Emergency Medical Services
</div>
<div class='FieldValue'>
Hospital Inpatient
</div>
<div class='FieldValue'>
Hospital Outpatient
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Professionals Involved in Delivery of Health Services
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Least Aggregated Level of Services Delivery Addressed
</h3>
<div class='FieldValue'>
Clinical Practice or Public Health Sites
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Statement of Acceptable Minimum Sample Size
</h3>
<div class='FieldValue'>
Unspecified
</div>

</div>
<div class='field field_text'>
<h3>
Target Population Age
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Age greater than or equal to 12 years</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Target Population Gender
</h3>
<div class='FieldValue'>
Female (only)
</div>

</div>

</div>
<div class='section'>
<h2>National Strategy for Quality Improvement in Health Care
</h2>
<div class='field field_text'>
<h3>
National Quality Strategy Aim
</h3>
<div class='FieldValue'>
<ul><li>Better Care</li></ul>
</div>

</div>
<div class='field field_text'>
<h3>
National Quality Strategy Priority
</h3>
<div class='FieldValue'>
<ul><li>Person- and Family-centered Care</li><li>Prevention and Treatment of Leading Causes of Mortality</li></ul>
</div>

</div>

</div>
<div class='section'>
<h2>Institute of Medicine (IOM) National Health Care Quality Report Categories
</h2>
<div class='field field_picklist-choice'>
<h3>
IOM Care Need
</h3>
<div class='FieldValue'>
Living with Illness
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
IOM Domain
</h3>
<div class='FieldValue'>
Effectiveness
</div>
<div class='FieldValue'>
Patient-centeredness
</div>

</div>

</div>
<div class='section'>
<h2>Data Collection for the Measure
</h2>
<div class='field field_text'>
<h3>
Case Finding Period
</h3>
<div class='FieldValue'>
<div class="content_para"><p>1 January to 31 October</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Denominator Sampling Frame
</h3>
<div class='FieldValue'>
Patients associated with provider
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Denominator (Index) Event or Characteristic
</h3>
<div class='FieldValue'>
Clinical Condition
</div>
<div class='FieldValue'>
Diagnostic Evaluation
</div>
<div class='FieldValue'>
Encounter
</div>
<div class='FieldValue'>
Patient/Individual (Consumer) Characteristic
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Denominator Time Window
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions<br />
</strong>Female children 12 years and more who were commenced on antiepileptic drugs (AEDs) </p>
<p><em>Clinical Cohort Ascertainment</em>: An initial heterogeneous group will be identified from electroencephalogram (EEG) services who will identify the potentially eligible group by identifying all children referred for a first EEG between 1 January and 31 October 2013. The EEG service will forward a list of all cases identified on a monthly basis to the audit unit lead who will filter the cases to form the cohort by application of inclusion and exclusion criteria. Refer to the original measure documentation for additional information. </p>
<p><em>Inclusion Criteria</em>:</p>
<ul style="list-style-type: disc;">
    <li>First EEG between 1 January and 31 October 2013. </li>
    <li>The child has a 'first paediatric assessment' for the 'paroxysmal episode or episodes' between 1 January and 30 April 2013. </li>
    <li>Child is older than 1 month and younger than 16 years at 'first paediatric assessment'. </li>
    <li>The EEG was prompted by the patient having one or more afebrile paroxysmal episodes. </li>
</ul>
<p class="Note"><strong>Note</strong>:</p>
<ul class="Note" style="list-style-type: disc;">
    <li><em>AEDs</em>: Regular daily drug treatment for reduction of risk of epileptic seizures in epilepsy. Not including drug treatment given for during a prolonged seizure (e.g., rectal diazepam/paraldehyde, buccal midazolam, intravenous [IV] lorazepam/phenytoin) or clusters of seizures (e.g., intermittent clobazam). Not including drugs where the purpose of treatment is for something other than epilepsy treatment (e.g., carbamazepine [CBZ] for behaviour, topiramate for migraine, etc.) </li>
    <li><em>First Paediatric Assessment</em>: A 'face to face' assessment by a secondary level/tier doctor in a paediatric service occurring in any non-acute or acute setting. Assessment within emergency department (ED) counts if performed by paediatric team rather than an ED team. Some paediatric neurologists see referrals direct from GP or ED and these would count as both a first paediatric assessment and tertiary input. </li>
    <li><em>Paroxysmal Episodes</em>: This is the term chosen in this audit to represent the events causing concern. It includes all epileptic and non-epileptic seizures and also seizures of uncertain origin. </li>
</ul>
<p><strong>Exclusions</strong></p>
<ul style="list-style-type: disc;">
    <li>All 'paroxysmal episodes' in question were diagnosed as 'febrile seizures'. (Children with a history of febrile seizures being assessed for different afebrile 'paroxysmal episodes' may be included.) </li>
    <li>The patient has had a paediatric assessment previously for similar episode or episodes or epilepsy prior to first paediatric assessment. </li>
    <li>All the paroxysmal episodes that the patient had were acute symptomatic seizures or occurred within a week of a traumatic head injury. </li>
    <li>The patient's care was permanently transferred to a secondary paediatric service outside the 'audit unit' boundaries or an adult service during the year after first paediatric assessment. </li>
</ul>
<p class="Note"><strong>Note</strong>:</p>
<ul class="Note" style="list-style-type: disc;">
    <li><em>Febrile Seizure</em>: An episode diagnosed by the assessing team as a 'febrile seizure' or 'febrile convulsion' or 'febrile fit'. </li>
    <li><em>Acute Symptomatic Seizures</em>: Seizures occurring at the time of a diagnosis of an acute disorder (e.g., meningitis, encephalitis, electrolyte disturbance, etc.). </li>
    <li><em>Audit Unit</em>: One or more secondary tier paediatric services grouped together using pragmatic boundaries agreed by the paediatric audit unit link, the project team and the tertiary link. </li>
</ul></div>
</div>

</div>
<div class='field field_picklist-choice-4'>
<h3>
Exclusions/Exceptions
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions</strong><br />
Female children 12 years and more who were commenced on antiepileptic drugs (AEDs) who had evidence of discussion regarding pregnancy and/or contraception </p>
<p><strong>Exclusions</strong><br />
Unspecified</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Numerator Search Strategy
</h3>
<div class='FieldValue'>
Fixed time period or point in time
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Data Source
</h3>
<div class='FieldValue'>
Electronic health/medical record
</div>
<div class='FieldValue'>
Paper medical record
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Type of Health State
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>
<div class='field field_text'>
<h3>
Instruments Used and/or Associated with the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Computation of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
Measure Specifies Disaggregation
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Scoring
</h3>
<div class='FieldValue'>
Rate/Proportion
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Interpretation of Score
</h3>
<div class='FieldValue'>
Desired value is a higher score
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Allowance for Patient or Population Factors
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Standard of Comparison
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>

</div>
<div class='section'>
<h2>Identifying Information
</h2>
<div class='field field_text'>
<h3>
Original Title
</h3>
<div class='FieldValue'>
<div class="content_para"><p>12a. Percentage of females over 12 years given anti-epileptic drugs, who had documented evidence of discussion of pregnancy or contraception.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Collection Name
</h3>
<div class='FieldValue'>
Epilepsy12 Performance Indicators
</div>

</div>
<div class='field field_text'>
<h3>
Measure Set Name
</h3>
<div class='FieldValue'>
Management and Outcome
</div>

</div>
<div class='field field_orglist'>
<h3>
Submitter
</h3>
<div class='FieldValue'>
Royal College of Paediatrics and Child Health - Medical Specialty Society
</div>

</div>
<div class='field field_orglist-p'>
<h3>
Developer
</h3>
<div class='FieldValue'>
Royal College of Paediatrics and Child Health - Medical Specialty Society
</div>

</div>
<div class='field field_text'>
<h3>
Funding Source(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Composition of the Group that Developed the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Project Board </strong></p>
<ul style="list-style-type: disc;">
    <li>Dr. Helen Basu, Consultant Paediatric Neurologist, British Paediatric Neurology Association representative </li>
    <li>Alex Bird, Development Officer, Healthcare Quality Improvement Partnership </li>
    <li>Ann Brown, Epilepsy Specialist Nurse, Royal College of Nursing representative </li>
    <li>John Cowman, Director of Operations, Young Epilepsy </li>
    <li>Dr. Colin Dunkley, Consultant Paediatrician, Project lead </li>
    <li>Dr. Colin Ferrie, Consultant Paediatric Neurologist, Clinical representative </li>
    <li>Jacqueline Fitzgerald, Director of Policy and Research, RCPCH </li>
    <li>Dr. Martin Kirkpatrick, Consultant Paediatric Neurologist, Scotland and HIS representative </li>
    <li>Dr. Katherine Martin, Consultant in Paediatric Neurodisability, British Academy of Childhood Disability representative </li>
    <li>Dr. Lesley Notghi, Consultant Neurophysiologist, British Society for Clinical Neurophysiology representative </li>
    <li>Angie Pullen, Epilepsy Services Manager, Epilepsy Action </li>
    <li>Dr. Yvonne Silove, Associate Director for Quality and Improvement, National Clinical Audit and Patient Outcomes Programme, Healthcare Quality Improvement Partnership </li>
    <li>Anissa Tonberg, Policy and Development Manager, Epilepsy Scotland </li>
    <li>Berni Waldron, Epilepsy Specialist Nurse, Audit Facilitator </li>
</ul>
<p><strong>Methodology Working Group</strong> </p>
<ul style="list-style-type: disc;">
    <li>Katherine Bowyer, Neurophysiological Scientist </li>
    <li>Dr. Richard Chin, Consultant Paediatric Neurologist </li>
    <li>Dr. Colin Dunkley, Consultant Paediatrician </li>
    <li>Dr. Colin Ferrie, Consultant Paediatric Neurologist </li>
    <li>Dr. Katherine Martin, Consultant in Paediatric Neurodisability </li>
    <li>Berni Waldron, Epilepsy Specialist Nurse </li>
    <li>Dr. William Whitehouse, Senior Lecturer in Paediatric Neurology </li>
</ul></div>
</div>

</div>
<div class='field field_text'>
<h3>
Financial Disclosures/Other Potential Conflicts of Interest
</h3>
<div class='FieldValue'>
<div class="content_para"><p>No financial disclosures or potential conflicts of interest</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Adaptation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measure was not adapted from another source.</p></div>
</div>

</div>
<div class='field field_date'>
<h3>
Date of Most Current Version in NQMC
</h3>
<div class='FieldValue'>
2014 Nov
</div>

</div>
<div class='field field_text'>
<h3>
Measure Maintenance
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Measures are reviewed with consideration for update as national recommendations are updated and the audit cycle is repeated. This frequency will be removed as the audit evolves to continuous audit models.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Date of Next Anticipated Revision
</h3>
<div class='FieldValue'>
<div class="content_para"><p>2017</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the measure.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Availability
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Source available from the Royal College of Paediatrics and Child Health (RCPCH) Web site:</p>
<ul style="list-style-type: disc;">
    <li><a href="http://www.rcpch.ac.uk/system/files/protected/page/Epilepsy12%20report%202014%20for%20web.pdf" title="Royal College of Paediatrics and Child Health (RCPCH) Web site">Epilepsy12 national report, round 2.</a> </li>
    <li><a href="http://www.rcpch.ac.uk/system/files/protected/page/Full%20Methodology%20doc%2027Jun2013%20-%20posted%20online%2022Aug13.pdf" title="Royal College of Paediatrics and Child Health (RCPCH) Web site">Epilepsy12, round 2. Full methodology document.</a> </li>
</ul>
<p>For more information, contact RCPCH at 5-11 Theobald's Road, London WC1X 8SH, UK; Phone: +44 (0)20 7092 6000; E-mail: <a href="mailto:epilepsy12@rcpch.ac.uk">epilepsy12@rcpch.ac.uk</a>; Web site: <a href="http://www.rcpch.ac.uk/" title="Royal College of Paediatrics and Child Health (RCPCH) Web site">www.rcpch.ac.uk/</a>.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
NQMC Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NQMC summary was completed by ECRI Institute on June 10, 2016. The information was verified by the measure developer on June 26, 2016. </p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Copyright Statement
</h3>
<div class='FieldValue'>
<div class="content_para"><p>No copyright restrictions apply.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Production
</h2>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>The Royal College of Paediatrics and Child Health. Epilepsy12 national report, round 2. London (UK): The Royal College of Paediatrics and Child Health; 2014 Nov. 103 p. </td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>The Royal College of Paediatrics and Child Health. Epilepsy12, round 2. Full methodology document. London (UK): The Royal College of Paediatrics and Child Health; 2013 Jun. 33 p. </td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Disclaimer
</h2>
<div class='field field_text'>
<h3>
NQMC Disclaimer
</h3>
<div class='FieldValue'>
<p>The National Quality Measures Clearinghouseâ„¢ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.</p> 
<p>All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.</p> 
<p>Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the <a href="/help-and-about/summaries/inclusion-criteria">NQMC Inclusion Criteria</a>.</p> 
<p>NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding measure content are directed to contact the measure developer.</p>
</div>

</div>

</div>
</body></html>